Replies to post #103190 on Biotech Values

[DewDiligence]

Compare Aug 20 with Jun 18, new script was down 34.2%, total script down 35.7%. This might be proxy of initial generic market share around 35%.

Yes, and this is consistent with MNTA’s assertion that NVS can supply 35-40% of the market at present.